QTX-3034

Quanta Therapeutics received FDA IND clearance for QTX3544, an oral G12V-preferring multi-KRAS inhibitor, marking their third IND clearance within a year.

Quanta Therapeutics has announced the dosing of the first patient in a Phase 1 clinical trial for QTX3046, a novel oral KRASG12D-selective inhibitor, targeting advanced solid tumors with KRASG12D mutations. The trial also explores the combination of QTX3034, a G12D-preferring multi-KRAS inhibitor, with cetuximab for colorectal cancer patients. Additionally, GLP toxicology studies for QTX3544, a G12V-preferring KRAS inhibitor, have been initiated, supporting an anticipated IND filing in late 2024.

Quanta Therapeutics received FDA IND clearance for QTX3034, a G12D-preferring multi-KRAS inhibitor, paving the way for Phase 1 trials in Q1 2024.

AstraZeneca has licensed UA022, a novel KRAS G12D inhibitor, from Chinese biotech Usynova for $24 million upfront, with potential milestone payments reaching $395 million.